american heart association glp-1 receptor agonists as promising anti-inflammatory agents in failure with preserved ejection fraction | Heart Failure Reviews Comprehensive Overview of GLP-1 RAs

Theoretical Long-Term Risks TB500 enhances angiogenesis and cellular proliferation, which has raised concerns primarily in preclinical models about: Accelerating growth of dormant tumors Disrupting immune surveillance Overstimulating wound healing in healthy tissues There is no conclusive evidence that TB500 causes cancer, but its role in cell migration warrants caution, especially at high doses or long-term use without breaks

has served as a consultant or speaker within the past 12 months for Eli Lilly and Structure Therapeutics

This is not a comprehensive list

These medications, known as GLP-1 receptor agonists, were originally developed to help people with type 2 diabetes manage their blood sugar